Breast cancer survivors with lymphedema experience physical, psychosocial, and quality-of-life difficulties. Cancer treatment-related lymphedema often is viewed as a disabling condition, and that assumption has fostered an environment in which oncology nurses are not actively involved in the care of patients with lymphedema. Little is known about how breast cancer survivors with lymphedema structure their daily lives. This article describes an effort to determine whether lymphedema truly is a disabling condition by collecting symptom data and self-generated narratives from breast cancer survivors with lymphedema regarding their eating habits, daily activities, substance use, and future plans. Although the sample experienced multiple symptoms, lymphedema duration and degree of extracellular arm fluid did not appear to influence those symptoms. In addition, participants led full, rich, busy lives. The findings do not support the notion that patients with lymphedema live as disabled people. A disability model may not be optimal to guide research design or patient care; rather, a symptom management model better explains the findings and implies that active involvement by nurses in lymphedema patient care and education is indicated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1188/12.CJON.609-614 | DOI Listing |
Front Med (Lausanne)
January 2025
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Sodium-glucose co-transporter two inhibitors (SGLT2is) are widely used in clinical practice due to their proven cardiovascular and renal benefits. However, various adverse drug reactions (ADRs) have been reported. This study aims to systematically update the ADRs associated with SGLT2is and identify the differences among various SGLT2is acovigilance of various SGLT-2 inhibitors.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Malignant adenomyoepithelioma (MAME) of the breast is a rare tumor with both benign and malignant features. We report a case of a 67-year-old woman who presented with a mass in the outer quadrant of the right breast, detected during a routine check-up. The mass was classified as BI-RADS 3.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Purpose: Studies have shown that gut microbiota is involved in the tumorigenesis and development of prostate cancer. We aimed to perform a comprehensive analysis of causal associations of gut microbiota, metabolites, and cytokines with prostate cancer in the Asian population.
Patients And Methods: Genome-wide association study (GWAS) summary datasets were collected from the public databases.
Front Oncol
January 2025
Department of Oncology, Tawam Hospital, Al Ain, United Arab Emirates.
Breast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancer-related mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for patients in metastatic settings. The recognition of "HER2-low" expression as a targetable category has caused a paradigm shift in the management of breast cancer.
View Article and Find Full Text PDFBreast Cancer (Dove Med Press)
January 2025
Clinic for Plastic, Aesthetic and Reconstructive Surgery, Spine, Orthopedic and Hand Surgery, Preventive Medicine - ETHIANUM, Heidelberg, 69115, Germany.
Background: Adipokines, bioactive peptides secreted by adipose tissue, appear to contribute to breast cancer development and progression. While numerous studies suggest their role in promoting tumor growth, the exact mechanisms of their involvement are not yet completely understood.
Methods: In this project, varying concentrations of recombinant human adipokines (Leptin, Lipocalin-2, PAI-1, and Resistin) were used to study their effects on four selected breast cancer cell lines (EVSA-T, MCF-7, MDA-MB-231, and SK-Br-3).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!